ScholarDeck

Cohort studyJournal of clinical medicine · 2026

The Long-Term Evolution of Macular Retinoschisis in Eyes with Myopic Choroidal Neovascularization Treated with Anti-Vascular Endothelial Growth Factors.

Han-Hao Tsai, Fang-Ting Chen

OphthalmologyCohort study

Baseline macular retinoschisis strongly predicts its progression after anti-VEGF treatment

The Long-Term Evolution of Macular Retinoschisis in Eyes with Myopic Choroidal Neovascularization Treated with Anti-Vascular Endothelial Growth Factors.

Han-Hao Tsai, Fang-Ting Chen

Journal of clinical medicine · 2026

Background

To investigate the structural changes and visual outcomes in eyes with myopic choroidal neovascularization (mCNV) treated with anti-vascular endothelial growth factor (anti-VEGF) compared with fellow eyes over a long-term follow-up period.

Methods

A retrospective paired-eye cohort study was conducted, and 51 patients (80.4% female, mean age 51.8 years) with an average follow-up duration of 32.8 months were enrolled.

n = 51 patients

Results

eyes with schisis at the start were far more likely to see it worsen

Baseline MRS present

70%

Baseline MRS absent

17.1%

“

Conclusion · 1 of 2

Anti-VEGF treatment in mCNV eyes did not increase the incidence of macular retinoschisis compared with fellow eyes or aggravate macular retinoschisis.

Conclusion · 2 of 2

However, the presence of macular retinoschisis at baseline may increase the risk of macular retinoschisis progression after treatment, and close monitoring of this subgroup is warranted.

Post

The Long-Term Evolution of Macular Retinoschisis in Eyes with Myopic Choroidal Neovascularization Treated with Anti-Vascular Endothelial Growth Factors.

Baseline macular retinoschisis strongly predicts its progression after anti-VEGF treatment

Related papers